AstraZeneca (NYSE:AZN) is set to post its quarterly earnings results before the market opens on Thursday, October 24th. Analysts expect AstraZeneca to post earnings of $0.45 per share for the quarter. AstraZeneca has set its FY19 guidance at $3.50-3.70 EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.
AstraZeneca (NYSE:AZN) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.73 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.43. AstraZeneca had a net margin of 9.38% and a return on equity of 35.83%. The firm had revenue of $5.72 billion for the quarter, compared to the consensus estimate of $5.57 billion. During the same period in the previous year, the company earned $0.69 earnings per share. The company’s quarterly revenue was up 10.9% on a year-over-year basis. On average, analysts expect AstraZeneca to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
AZN stock opened at $43.92 on Wednesday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.75 and a current ratio of 0.95. The company’s 50-day simple moving average is $44.07 and its 200 day simple moving average is $41.56. AstraZeneca has a 52 week low of $35.30 and a 52 week high of $46.22. The company has a market capitalization of $116.32 billion, a PE ratio of 25.39, a price-to-earnings-growth ratio of 1.48 and a beta of 0.47.
Several equities analysts recently commented on AZN shares. HSBC restated a “sell” rating on shares of AstraZeneca in a research note on Thursday, October 17th. Argus upped their price target on shares of AstraZeneca to $50.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. DZ Bank downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Tuesday, September 3rd. Zacks Investment Research downgraded shares of AstraZeneca from a “strong-buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research note on Thursday, October 3rd. Finally, ValuEngine downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Four equities research analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $46.53.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: Moving Average Convergence Divergence (MACD)
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.